FIELD: medicine.
SUBSTANCE: invention refers to biotechnology and immunology. There are described antibodies and their functional equivalents specifically binding to RSV. Also, the invention refers to nucleotide sequences coding the above antibody, as well as to the cells producing antibodies, and to methods for producing the above antibodies.
EFFECT: invention can be used in medicine.
23 cl, 4 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RSV-SPECIFIC ANTIBODIES AND THEIR FUNCTIONAL PARTS | 2015 |
|
RU2785598C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| BISPECIFIC MOLECULES, IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR | 2014 |
|
RU2721707C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
| ANTIBODIES TO PD-1 | 2015 |
|
RU2715628C2 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| ANTIGENIC POLYPEPTIDES BASED ON THE RESPIRATORY SYNCYTIAL VIRUS SEQUENCE | 2019 |
|
RU2807992C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
